Placental Protein 13 Serum Endoglin and Uterine Doppler Indeces as Predictors of Pre-eclampsia

Preeclampsia Clinical Trial

Official title:

Maternal Serum Placental Protein 13 Serum Endoglin and Uterine Doppler Indeces as Predictors of Pre-eclampsia and Relation to Maternal and Neonatal Outcome

Clinical Trial Details — Status: Completed

Administrative data

• NCT number: NCT02350036
• Other study ID #: 125
• Status: Completed
• Phase: N/A
• First received: January 26, 2015
• Last updated: March 18, 2017
• Start date: January 2015
• Est. completion date: December 2016

Study information

• Verified date: March 2017
• Source: Cairo University
• Contact: n/a
• Is FDA regulated: No
• Study type: Observational [Patient Registry]

Clinical Trial Summary

50 pregnant females were divided in two groups, twenty five as a control group and twenty five as high risk group; they were subjected to uterine artery Doppler, measurement of maternal serum and detection of (MTHFR) gene polymorphisms in first trimester at 11 to 14 weeks of gestation, all pregnancies were followed until 40 weeks for development of pre-eclampsia

Description:

50 pregnant females were divided in two groups, twenty five as a control group and twenty five as high risk group; they were subjected to uterine artery Doppler, measurement of maternal serum (pp-13) and detection of (MTHFR) gene polymorphisms in first trimester at 11 to 14 weeks of gestation, all pregnancies were followed until 40 weeks for development of pre-eclampsia

Recruitment information / eligibility

• Status: Completed
• Enrollment: 50
• Est. completion date: December 2016
• Est. primary completion date: December 2016
• Accepts healthy volunteers: Accepts Healthy Volunteers
• Gender: Female
• Age group: 20 Years to 40 Years

Eligibility

Inclusion Criteria:

• pregnant women at 11 to 14 weeks of gestation

Exclusion Criteria:

• fetal anomalies other medical diseases as diabetes mellitus, renal or liver diseases

Related Conditions & MeSH terms

• Eclampsia
• Pre-Eclampsia
• Preeclampsia

Intervention

Other:
• ultrasound monitoring
Uterine artery Doppler assessment

Locations

Country	Name	City	State
Egypt	Kasr Alainy medical school	Cairo

Sponsors (1)

Lead Sponsor	Collaborator
Cairo University

Country where clinical trial is conducted

Egypt, 

Outcome

Type	Measure	Description	Time frame	Safety issue
Primary	development of preeclampsia		40 weeks pregnancy